DRUG NAME CLASSIFICATION MECHANISM OF ACTION INDICATION/CONTRAINDICATION ADVERSE REACTION NURSING RESPONSIBILITIES

* MUCOLYTICS * REDUCE THE VISCOSITYOF INDICATION: CNS: FEVER, DROWSINESS * MONITOR COUGH TYPE AND
ACETYLCYSTEINE PULMONOARY SECRETIONS * ADJUNCTIVE THERAPY FOR ABNORMAL CV: CHEST TIGHTNESS, FREQUENCY
BY SPLITTING DISULPHIDE VISCID OR THICKENED MUCOUS FLUSHIN, TACHYCARDIA, * WARN PATIENT THAT DRUG
LINKAGES BETWEEN SECRETIONS EDEMA MAY HAVE A FOUL TASTE OR
MUCOPROTREIN GI: NAUSEA, STOMATITIS, SMELL THAT MAY BE
MOLECULAR COMPLEXES. MUCOLYTIC IN RESPIRATORY DISORDERS VOMITING DISTRESSING
ALSO, RESTORES LIVER ASSOCIARED WITH PRODUCTIVE COUGH RESPIRATORY: * FOR MAXIMUM EFFECT,
STORES OF GLUTHATHIONE BRONCHOSPASM, COUGH, INSTRUCT PATIENT TO
TO TREAT ACETAMINOPHEN CONTRAINDICATION: DYSPNEA, RHONCHI COUGH TO CLEAR HIS
TOXICITY HYPERSENSITIVITY AIRWAY

DRUG NAME CLASSIFICATION MECHANISM OF ACTION INDICATION/CONTRAINDICATION ADVERSE REACTION NURSING RESPONSIBILITIES

* LIPID LOWERING AGENT * ATORVASTATIN INDICATION: * Arthralgia, dyspepsia, * Obtain baseline cholesterol,
ATORVASTATIN COMPETITIVELY INHIBITS 3- * IT IS USE TO LOWER CHOLESTEROL IF YOU’VE diarrhea, nausea, triglycerides, and liver function
HYDROXY-3- BEEN DIAGNOSED WITH HIGH CHOLESTEROL AND nasopharyngitis, insomnia, tests.
METHYLGLUTARYL- PREVENT HEART DISEASE, INCLUDING HEART urinary tract infection, and * Monitor liver function and
COENZYME A(HMG-CoA) ATTACKS AND STROKES. pain in the extremities. creatine kinase level.
REDUCTASE BY PREVENTING * Assess for signs of muscle
THE CONVERSION OF HMG-CoA weakness or pain.
TO MEVALONATE, STATIN CONTRAINDICATION: * Monitor for EKG changes.
MEDICATIONS DECREASE * HYPERSENSITIVITY TO AT0RVASTATIN * Assess for changes in
CHOLESTEROL PRODUCTIONIN concentration, alertness, and
THE LIVER vision.

LAJO, MARY QUEEN C.

GROUP: 10-C
DRUG NAME CLASSIFICATION MECHANISM OF ACTION INDICATION/CONTRAINDICATION ADVERSE REACTION NURSING
RESPONSIBILITIES

CITICOLINE NEUROTROPIC * CITICOLINE IS A INDICATION: CARDIOVASCULAR: * ASSESS FOR ALLERGIES

DERIVATIVE OF CHOLINE * CITICOLINE IS INDICATED FOR IMMEDIATE BRADYCARDIA, * ADVICE THE CLIENT TO
AND CYTIDINE INVOLVED TREATMENT OF STROKE DUE TO A CLOT TACHYCARDIA, USE CAUTION WHEN
IN THE BIOSYNTHESIS OF ISCHEMIC STROKE HYPERTENSION ENGAGING IN TASKS THAT
LECITHIN. IT IS CLAIMED GI: DIARRHEA, EPIGASTRIC REQUIRE ALERTNESS IF
TO INCREASE BLOOD FLOW CONTRAINDICATION: DISTRESS, STOMACH PAIN DIZZINESS IS PRESENT
AND OXYGEN * HYPERSENSITIVITY TO CITICOLINE NERVOUS: DIZZINESS, * GUARD AGAINST FALLS
CONSUMPTION IN THE * HYPERTONIC OF THE PARASYMPATHETIC HEADACHE. FATIGUE AND TRAUMA. IMPLEMENT
BRAIN FALL PREVENTION
STRATEGIES LIKE RAISING
TWO SIDE RAILS.

DRUG NAME CLASSIFICATION MECHANISM OF ACTION INDICATION/CONTRAINDICATION ADVERSE REACTION NURSING

RESPONSIBILITIES

GLARGINE * LONG-ACTING * LOWER BLOOD GLUCOSE BY INDICATION: METABOLIC: * GIVE MAINTENANCE

INSULINS INCREASING TRANSPORT INTO
CELLS AND PROMOTING THE
CONVERSION OF GLUCOSE
GLYCOGEN. PROMOTES THE
CONVERSION OF AMINO ACIDS TO
PROTEIN IIN MUSCLE AND
STIMULATESTRIGLYCERIDE
FORMATION. INHIBITS RELEASE OF
FREE FATTY ACIDS.
* GLARGINE IS INDICATED TO IMPROVE HYPOGLYCEMIA DOSES SUBCUTANEOUSLY,
GLYCEMIC CONTROL IN ADULTS AND PEDIA SKIN: LIPODYSTROPHY, ROTATING INJECTION STE
WITH TYPE 1 DIABETES MELLITUS AND IN RASH ARE REGULARLY TO
ADULT WITH TYPE 2 DIABETES MELLITUS OTHER: ALLERGIC DECREASE
CONTRAINDICATION: REACTIONS, PAIN AT LIPODYSTROPHY
* GLARGINE MUST NOT BE USED IN PATIENTS INJECTION SITEE * MONITOR PATIENTS
HYPERSENSITIVE IN GLARGINE RECEIVING INSULIN IV
CAREFULLY
* MONITOR VITAL SIGNS
DRUG NAME CLASSIFICATION MECHANISM OF ACTION INDICATION/CONTRAINDICATION ADVERSE REACTION NURSING
RESPONSIBILITIES

LACTULOSE GASTROINTESTINAL * REDUCES BLOOD INDICATION: GI: FLATULENCE, * PROMOTE FLUID INTAKE
AGENT: HYPEROSMOTIC AMMONIA BY ACIDIFYING * PREVENTION AND TREATMENT OF PRTAL- BORBORYGMI, DURING DRUG THERAPY
LAXATIVE COLON CONTENTS, THUS SYSTEMIC ENCEPHALOPATTY (PSE), BELCHING, FOR CONSTIPATION
RETARDING DIFFUSION OF INCLUDING STAGES OF HEPATIC PRECOMA ABDOMINAL CRAMPS, * ASSESS CONDITION
NON-IONIC AMMONIA FROM AND COMA, AND BY PRESCRIPTION FOR PAIN AND DISTENTION BEFORE THERAPY AND
COLON TO BLOOD WHILE RELIEF OF CHRONIC CONSTIPATION REASSESS REGULARLY
PROMOTING ITS MIGRATION CONTRAINDICATION: THERE AFTER TO
FROM BLOOD TO COLON * LOW GALACTOSE DIET MONITORING’S
EFFECTIVENESS
- MONITORPT FOR ANY
ADVERSE GI REACTION,
NAUSEA, VOMITING,
DIARRHEA
- MONITOR I AND O
DRUGNAME CLASSIFICATION MECHANISM OF ACTION INDICATION/CONTRAINDICATION ADVERSE REACTION NURSING
RESPONSIBILI

GENERIC NAME: * ANGIOTENSIN II RECEPTOR * LOSARTAN IS AN INDICATION: GI: RENAL FAILURE, REANAL * MONITOR
LOSARTAN (TYPE AT1) ANTAGONIST ANGIOTENSIN II RECEPTOR * INDICATED FOR PATIENTS WITH INSUFFIEMCY, HYPERKALEMIA SYMPTOMS OF
BLOCKER (ARB). IT WORKS BY HYPERTENSION TO REDUCE BLOOD PRESSURE HEMA: ANEMIA, ANGIOEDEMA HIGH PLASMA
BLOCKING A SUBSTANCE IN CARDIO: CHEST PAIN, ATRIAL POTASSIUM
THE BODY THAT CAUSES FIBRILLATION, PALPITATIONS LEVELS
BLOOD VESSELS TO TIGHTEN. CONTRAINDICATION: NEURO: TINNITUS (HYPRKALEMI
AS A RESULT, LOSARTAN FOR THOSE WITH HYPERSENSITIVITY TO INCLUDING
RELAXES THE BLOOD LOSARTAN OR ANY OF ITS EXCIPIENTS BRADYCARDI
VESSELS. AA LOWER BLOOD * CONCOMITANT USE WITH ALISKIREN FATIGUE,
PRESSURE WILL INCREASE CONTAINING PRODUCTS IN PATIENTS WITH WEAKNESS,
THE SUPPLY OF THE BLOOD DIABETES MELLITUS OR RENAL FAILURE NUMBENESS, A
AND OXYGEN TO THE HEART. TINGLING
* NOTIFY
PHYSICIAN
BECAUSE SEV
CASES CAN LE
TO LIFE-
THREATENING
ARRYTHMIAS
PARALYSIS
* MONITOR SII
OF
HYPOGLYCEM
ESPECIALLY
DURING AND
AFTER EXERC
DRUG NAME CLASSIFICATION MECHANISM OF ACTION INDICATION/CONTRAINDICATION ADVERSE REACTION NURSING RESPONSIBILI

NEPHROSTERIL PRESCRIPTION DRUG * REDUCES BLOOD AMMONIA INDICATION: NAUSEA, VOMITING, * PROMOTE FLUID INTA
BY ACIDIFYING COLON * BALANCED SUPPLY OF PROTEIN ELEMENTS IN SHIVERING AND CHILLS DURING DRUG THERAPY
CONTENTS, THUS RETARDING ACUTE AND CHRONIC RENAL INSUFFICIENCY AS FOR CONSTIPATION
THE DIFFUSION OF NON-IONIC WELL AS DURING PERITONEAL AND * ASSESS CONDITION
AMMONIA FROM COLON TO HEMODIALYSIS TREATMENT BEFORE THERAPY AND
BLOOD WHILE PROMOTING CONTRAINDICATION: REASSESS REGULARLY
ITS MIGRATION FROM BLOOD * IMPAIRED AMINO ACID METABOLISM, THERE AFTER TO
TO COLON ADVANCED FUNCTIONAL IMPAIRMENT OF THE MONITORING’S
LIVER, SEVERE, CARDIAC INSUFFICIENCY, EFFECTIVENESS
HYPERHYDRATION, HYPOKALEMIA, - MONITORPT FOR ANY
HYPONATREMIA ADVERSE GI REACTION,
NAUSEA, VOMITING,
DIARRHEA
- MONITOR I AND O

DRUG NAME CLASSIFICATION MECHANISM OF ACTION INDICATION/CONTRAINDICATION ADVERSE REACTION NURSING

RESPONSIBILITIES

PIPTAZ GASTROINTESTINAL *ANTIBACTERIAL INDICATION: CNS: HEADACHE, INSOMNIA, * OBTAIN HISTORU OF

AGENT: HYPEROSMOTIC COMBINATION PRODUCT * TREATMENT OF UNCOMPLICATED AND FEVER HYPERSENSITIVITY TO
LAXATIVE CONSISTING OF THE COMPLICATED SKIN AND SKIN STRUCTURE GI: DIARRHEA, PENICILLINS
SEMISYNTHETIC INFECTIONS, BETA-LACTAMASE PRODUCING CONSTIPATION, NAUSEA, * LAB TESTS
PIPERACILLIN AND THE BACTERIA VOMITING, DYSPEPSIA, -C&S PRIOR TO FIRST DOSE
BETA-LACTAMASE CONTRAINDICATION: PSEUDOMEMBRANOUS OF THE DRUG
INHIBITOR TAZOBACTAM. * HYPERSENSITIVITY TO PIPERACILLIN COLITIS - MONITOR HEMATOLOGIC
TAZOBACTAM COMPONENT TAZOBACTAM, PENICILLINS, CEPHALOSPORINS SKIN: RASH, STATUS WITH PROLONGED
DOES NOT DECREASE THE OR BETA-LACTAMASE INHIBITORS SUCH AS HYPERSENSITIVITY REACTION THERAPY
ACTIVITY OF THE CLAVULANIC ACID AND SULBACTAM
PIPERACILLIN COMPONENT
AGAINST SUSCEPTIBLE
ORGANISMS
DRUG NAME CLASSIFICATION MECHANISM OF ACTION INDICATION/CONTRAINDICATION ADVERSE REACTION NURSING RESPONSIBILIT

POTASSIUM CHLORIDE ELECTROLYTES * MAINTAIN ACID-BASE INDICATION: CNS: CONFUSION, * OBSERVE 14 RIGHTS OF
BALANCE, ISOTONICITY AND * PREVENTION AND CORRECTION OF POTTASIUM RESLESNESS, MEDICATIONS
ELECTROPHYSIOOGIC DEFICIENCY WEAKNESS OR * PATIENTS AT INCREASE
BALANCE OF THE CELL. * TO PREVENT HYPOKALEMIA HEAVINESS OF LIMBS, RISK FOR GI LESIONS WH
ACTIVATOR IN MANY CONTRAINDICATION: FLACCID PARALYSIS, TAKING ORAL POTASSIUM
ENZYMATIC REACTIONS; * CONTRAINDICATED IN PATIENTS PARESTHESIA OF LIMBS, INCLUDE THOSE WITH
ESSENTIAL TO TRANSMISSION HYPERSENSITIVE TO POTASSIUM CHLORIDE OR LISTLESSNESS SCLERODEMA, DIABETES
OF NERVE IMPULSES, COMPONENTS OF THE FORMULATION, IN CV: ARRHYTMIAS, MITRAL VALVE
CONTRACTION OF CARDIAC, PATIENTS WITH RENAL FAILURE AND IN THOSE CARDIAC ARREST, REPLACEMENT
SKELETAL, AND SMOOTH WITH CONDITIONS IN WHICH POTASSIUM HEART BLOCK, ECG * MONITOR CONTINUES
MUSCLE, GASTRIC RETENTIN ID PRESENT CHANGES, ECG AND ELECTROLYTE
SECRETION; RENAL HYPOTENSION, LEVELS DURING THERAP
FUNCTION, TISSUE POSTINFUSION
SYNTHESIS; AND PHLEBITIS
CARBOHYDRATE GI: ABDOMINAL PAIN,
METABOLISM DIARRHEA,
FLATULENCE, NAUSEA,
VOMITING, GI
ULCERATION, STENOTIC
LESIONS
METABOLIC:
HYPERKALEMIA

DRUG NAME CLASSIFICATION MECHANISM OF ACTION INDICATION/CONTRAINDICATION ADVERSE REACTION NURSING RESPONSIBILITIE

SALBUTAMOL NEBU * STIMULATES BETA2- INDICATION: HEADACHE, * BASELINE ASSESSMENT

ADRENERGIC RECEPTORS IN * ACUTE BRONCHOSPASM, EXACERBATION OF RESTLESSNESS, - ASSESS LUNG SOUND, PUL
LUNGS, RESULTING IN ASTHMA, CHRONIC BRONCHOSPASM NERVOUSNESS, B/P, CHARACTERISTICS OF
RELAXATION OF BRONCHIAL CONTRAINDICATION: TREMORS, NAUSEA, SPUTUM
SMOOTH MUSCLE. * HYPERSENSITIVITY TO ALBUTEROL. DIZZINESS, THROAT * MONITOR RATE, DEPTH,
DRYNESS AND RHYTHM, TYPE OF
IRRITATION RESPIRATORY; QUALITY AN
RATE OF PULSE; EKG